No evidence of hypercoagulability, altered fibrinolysis, or increased fibrin(ogen) microaggregates in never-hospitalized long COVID - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

No Signs of Hypercoagulability, Impaired Fibrinolysis, or Elevated Fibrin(ogen) Microaggregates in Long COVID Patients Never Hospitalized

  • By

  • Emily Fraser

  • Kher Ng

  • Neda Hasan

  • Isobel Dunstan

  • Avianna Laws

  • Fraser Macrae

  • Jeries Abu-Hanna

  • Robert Ariens

  • Victoria Harris

  • Jason Oke

  • Laura Saunders

  • James Grist

  • Guilhem Collier

  • Paul Hughes

  • Jim Wild

  • Roger Thompson

  • Fergus Gleeson

  • Susan Shapiro

  • October 19, 2026

Share

Objective:

To assess whether people with long COVID who had never been hospitalized show evidence of hypercoagulability, altered fibrinolysis, or increased fibrin(ogen) microaggregates.

Interpretation:

The supplied context provides the article title and author affiliations but no study methods, results, or author interpretation.

Limitations:
  • No study design, participant details, measurements, or results were provided in the supplied context.

Original Source(s)

No evidence of hypercoagulability, altered fibrinolysis, or increased fibrin(ogen) microaggregates in never-hospitalized long COVID

  • by Emily Fraser, Kher Ng, Neda Hasan, Isobel Dunstan, Avianna Laws, Fraser Macrae, Jeries Abu-Hanna, Robert Ariens, Victoria Harris, Jason Oke, Laura Saunders, James Grist, Guilhem Collier, Paul Hughes, Jim Wild, Roger Thompson, Fergus Gleeson, Susan Shapiro

  • October 19, 2026

Related Content

CRISPR-Based Delivery System Generates CAR T Cells In Vivo

A two-vector delivery system generates tumor-targeting CAR T cells directly inside the body, achieving complete responses in mouse cancer models

  • October 13, 2026

  • 3 min
Musings From the Power List: Jason Bock

Jason Bock shares his outlook on RNA-targeting therapies, personalized medicine, and the future of drug development

Glucagon-like peptide-1 receptor agonists and risk for hematologic malignancies: a multicenter propensity score-matched analysis